Genetic Technologies Limited (NASDAQ:GENE)

Genetic Technologies was the first company in the world to recognize important new applications for non-coding DNA (DeoxyriboNucleic Acid). The Company has since been granted patents securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all multicellular species.

Genetic Technologies Limited (NASDAQ:GENE)’s Financial Overview

Genetic Technologies Limited (NASDAQ:GENE) surged 2.34% yesterday to close its trading session at $2.19. The company has 1 year Price Target of $12.5. Genetic Technologies Limited has 52-Week high of $3.52 and 52-Week Low of $1.2. The stock touched its 52-Week High on Dec 3, 2015 and 52-Week Low on Oct 28, 2016. The stock traded with the volume of 2.73 Million shares yesterday. The firm shows the market capitalization of $25.43 Million.

The firm is trading with SMA20 of 57.27 Percent, SMA50 of 41.04 Percent and SMA200 of 7.54 percent. Genetic Technologies Limited has P/S value of 42.38 while its P/B value stands at 2.84. Similarly, the company has Return on Assets of -61.9 percent, Return on Equity of -71.8 percent and Return on Investment of -71 Percent. The company shows Gross Margin and Operating Margin of 9.9 percent and 0 percent respectively.

Many brokerage firms are involved in issuing their ratings on Genetic Technologies Limited (NASDAQ:GENE). On 13-Feb-14 Ladenburg Thalmann Upgrade Genetic Technologies Limited Stock  to Buy. Another firm also rated the stock on 3-May-13 where Ladenburg Thalmann Upgrade the stock to Neutral.

The Stock currently has Analyst’ mean Recommendation of 3 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 1 analysts offering 12-month price forecasts for Genetic Technologies Ltd have a median target of 6.61, with a high estimate of 6.61 and a low estimate of 6.61. The median estimate represents a +201.83% increase from the last price of 2.19.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

Barrick Gold Corporation (NYSE:ABX)

Barrick Gold Corporation is a leading international gold producer with low-cost mines in North and South America.

Barrick Gold Corporation (NYSE:ABX)’s Financial Outlook

The 24 analysts offering 12-month price forecasts for Barrick Gold Corp have a median target of 23.00, with a high estimate of 30.00 and a low estimate of 14.94. The median estimate represents a +53.13% increase from the last price of 15.02.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

According to Zacks Investment Research, Barrick Gold Corporation has a Consensus Recommendation of 2.69. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock fell -2.72% and closed its last trading session at $15.02. The company has the market capitalization of $17.5 Billion. The stock has 52-week high of $23.47 and 52-Week low of $6.94. The firm touched its 52-Week high on Jul 6, 2016 and 52-Week low on Dec 17, 2015. The company has volume of 22.89 Million shares. The company has a total of 1.16 Billion shares outstanding.

Barrick Gold Corporation (NYSE:ABX) in the last quarter reported its actual EPS of $0.24/share where the analyst estimated EPS was $0.21/share. The difference between the actual and Estimated EPS is $0.03. This shows a surprise factor of 14.3 percent.

The company has YTD performance of 104.57 percent. Beta for Barrick Gold Corporation stands at -0.22 while its ATR (average true range) is 0.77. The company has Weekly Volatility of 3.23%% and Monthly Volatility of 4.75%%.

Barrick Gold Corporation has distance from 20-day Simple Moving Average (SMA20) of -6.87%, Distance from 50-Day Simple Moving Average of -9.25 percent and Distance from 200-Day Simple Moving Average of -14.15%.

The Company currently has ROA (Return on Assets) of -9.3 percent, Return on Equity (ROE) of -32.8 Percent and Return on Investment (ROI) of -13.5% with Gross margin of 35.7 percent and Operating & Profit margin of -18.4% and -28.2% respectively.